

Zydus Cadila's EBIDTA up by 108% in Q3

Ahmedabad, February 8, 2018

For the third quarter ended December 31, 2017, Zydus Cadila reported Earnings before Interest, Depreciation and Tax (EBIDTA) of Rs. 841 crores, up by 108% y-o-y. The total income from operations was up by 38% y-o-y to Rs. 3,260 crores and net profit was up 68% to Rs. 543 crores.

During the quarter, the company received approval for 24 new products for the US market and filed 10 additional ANDAs with the USFDA. The Company launched 2 new products in the US during the quarter. In India, the company launched 12 new products including line extensions during the quarter with 4 first in India launches.

During the quarter, the company received the marketing approval from the Mexican regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk) to commercialize Lipaglyn™ (Saroglitazar Magnesium) in Mexico for the treatment of Dyslipidemia in patients with diabetes mellitus type 2 and Hypertriglyceridemia in patients with diabetes mellitus type 2 not controlled by statins.

Taking its efforts in public health and care a step further, the company entered into a public private partnership with the Indian Council of Medical Research (ICMR) during the quarter, to launch new diagnostic kits, developed by ICMR's National Institute of Virology (NIV), Pune to detect neglected infectious diseases in livestock.
